Application of ALT711 in preparation of medicine for preventing and treating inflammatory bowel disease
By using the AGE inhibitor ALT711 to break the cross-linking of glycosylation end products, it is prepared into a variety of dosage forms of drugs, solving the problems of limited efficacy and high cost of existing inflammatory bowel disease treatments, significantly inhibiting weight loss and improving DAI scores , demonstrates its low toxic and efficient therapeutic potential in inflammatory bowel disease.
Patent Information
- Application Number
- CN202410903965.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-08
- Publication Date
- 2024-11-08
AI Technical Summary
Existing treatments for inflammatory bowel disease have limited efficacy, high recurrence rates, high cost and side effects, especially in patients with poor response to glucocorticoids or immunosuppressants or have serious adverse reactions. .
Using the AGE inhibitor ALT711 as a pharmaceutical ingredient, drug preparations in various dosage forms are prepared to prevent and treat inflammatory bowel diseases, including granules, common tablets, dispersed tablets, etc. , used to significantly inhibit weight loss and improve DAI scores and reduce colon shortening.
ALT711 significantly inhibits weight loss, improves DAI scores and reduces colon shortening in UC mice, demonstrates its low toxicity and high efficiency in the prevention and treatment of inflammatory bowel disease, and has the potential to become a low toxicity and high efficiency that can be administered orally. drug.
Smart Images

Figure CN118903117A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of inflammatory bowel disease medicine, and in particular to the use of ALT711 in preparing medicines for preventing and treating inflammatory bowel disease. Background Art
[0002] The AGE inhibitor ALT711, with CAS number 341028-37-3, is an inhibitor of advanced glycation end products (AGEs) that can break the cross-links caused by advanced glycation end products (AGEs). It has been shown to be effective in lowering systolic blood pressure and providing therapeutic benefits to patients with diastolic blood pressure.
[0003] Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), is a group of intestinal inflammatory diseases whose etiology and pathogenesis are not fully understood. Recently, it has been widely believed that IBD may be related to environmental factors, genetic susceptibility, immune abnormalities, and alterations in the intestinal microbiome. Due to its increasing incidence, IBD has become a common digestive disease in my country.
[0004] Existing clinical treatment drugs for IBD are mainly divided into two categories: non-biological agents and biologics. Non-biological agents include glucocorticoids, immunomodulators and aminosalicylic acids. These drugs have short half-lives, low production costs, and high patient dependence when taken orally. They can improve clinical symptoms but still have problems such as limited efficacy, high relapse rate, and long treatment cycle. Biologics include monoclonal antibodies, recombinant cytokines, and specific antagonists of receptors and cytokines. For patients who respond poorly or have no response to small molecule drugs such as glucocorticoids or immunosuppressants, and patients who have serious adverse reactions to other therapeutic drugs, biologics are a good alternative treatment option. However, in addition to potential side effects and response variability, the high cost of biologics also imposes a burden on financially disadvantaged patients and the medical insurance system.
[0005] At present, finding cheaper, less toxic, highly effective and orally administrable natural medicines for the treatment of inflammatory bowel disease still has important clinical value. Summary of the Invention
[0006] To address the aforementioned technical challenges in treating inflammatory bowel disease, the present invention provides the use of ALT711 in the preparation of a medicament for preventing or treating inflammatory bowel disease. Research has shown that the AGE inhibitor ALT711 can significantly inhibit weight loss, significantly improve the DAI scores of UC mice, and significantly reduce colon shortening in UC mice. This provides the use of ALT711 in the prevention and treatment of inflammatory bowel disease.
[0007] The specific technical solutions of the present invention are: In a first aspect, the present invention provides use of ALT711 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease.
[0008] This study found that ALT711 significantly inhibited weight loss in UC mice, significantly improved their DAI scores, and significantly reduced colon shortening in UC mice. This study also provides insights into the use of ALT711 in the prevention and treatment of inflammatory bowel disease. ALT711 is an inhibitor of advanced glycation end products (AGEs), breaking down crosslinks caused by these AGEs. It has been shown to be effective in lowering systolic blood pressure and providing therapeutic benefits in patients with diastolic blood pressure. This study is the first to demonstrate the role of ALT711 in the prevention and treatment of inflammatory bowel disease. ALT711 holds promise as a low-toxic, highly effective drug for the prevention and treatment of inflammatory bowel disease in humans.
[0009] As a preferred embodiment of the above technical solution, the dosage forms of the drug include granules, ordinary tablets, dispersible tablets, effervescent tablets, orally disintegrating tablets, lozenges, chewable tablets, capsules, soft capsules, microcapsules, pills, powders, pellets, sustained-release preparations, controlled-release preparations, oral liquid preparations and injections.
[0010] Based on the use of ALT711 in the prevention and treatment of inflammatory bowel disease provided by the present invention, ALT711 is used as the active ingredient, and one or more pharmaceutically acceptable excipients are added to ALT711 through conventional pharmaceutical means to prepare the resulting pharmaceutical preparations, such as granules, ordinary tablets, dispersible tablets, etc. The resulting pharmaceutical preparations can be used in the prevention and treatment of inflammatory bowel disease in humans.
[0011] In a second aspect, the present invention provides use of ALT711 in the preparation of a medicament for preventing and / or treating ulcerative colitis.
[0012] Further preferably, the dosage forms of the drug include granules, ordinary tablets, dispersible tablets, effervescent tablets, orally disintegrating tablets, lozenges, chewable tablets, capsules, soft capsules, microcapsules, pills, powders, dropping pills, sustained-release preparations, controlled-release preparations, oral liquid preparations and injections.
[0013] In a third aspect, the present invention provides a composition for treating inflammatory bowel disease, wherein the active ingredient of the composition is ALT711.
[0014] More preferably, the inflammatory bowel disease is ulcerative colitis.
[0015] Preferably, the composition comprises one or more pharmaceutically acceptable excipients.
[0016] Preferably, the composition is prepared into granules, ordinary tablets, dispersible tablets, effervescent tablets, orally disintegrating tablets, lozenges, chewable tablets, capsules, soft capsules, microcapsules, pills, powders, dripping pills, sustained-release preparations, controlled-release preparations, oral liquid preparations and injections.
[0017] Compared with the prior art, the present invention has the following technical effects: (1) The present invention found through research that ALT711 can significantly inhibit the weight loss of UC mice, significantly improve the DAI score of UC mice, and significantly reduce the shortening of the colon of UC mice, and provides the application of ALT711 in the prevention and treatment of inflammatory bowel disease.
[0018] (2) ALT711 is an inhibitor of advanced glycation end products (AGEs) that can break down cross-links caused by AGEs. It has been shown to be effective in lowering systolic blood pressure and providing therapeutic benefits to patients with diastolic blood pressure. This invention is the first to discover the role of ALT711 in the prevention and treatment of inflammatory bowel disease. ALT711 is expected to become a low-toxic, highly effective drug for use in the prevention and treatment of inflammatory bowel disease in humans. This invention can provide more low-toxic, highly effective drugs for the treatment of inflammatory bowel disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The results of the effect of ALT711 on DSS-induced UC mice in Example 1; Figure 2 These are the results of the effect of ALT711 on DSS-induced colon pathology in UC mice in Example 2. DETAILED DESCRIPTION
[0020] The present invention will be further described below with reference to the following embodiments. Those skilled in the art will be able to implement the present invention based on these descriptions. Furthermore, the embodiments of the present invention described below are generally only a portion of the embodiments of the present invention, rather than all of the embodiments. Therefore, all other embodiments derived by those skilled in the art based on the embodiments of the present invention without inventive effort should fall within the scope of protection of the present invention.
[0021] Example 1 This example used ALT711 to administer to DSS-induced UC mice and tracked the changes in body weight, disease activity index (DAI) scores, and spleen coefficient of the UC mice. The steps were as follows: Thirty male C57BL / 6 SPF mice (20 ± 2 g) were randomly divided into five groups (6 mice in each group) and treated as follows: Control group (denoted as Control group): blank control, without any treatment; Model group (denoted as Model group): positive control, free drinking of 3% DSS solution (mass fraction, the same below) for 7 days to induce UC; SASP group: UC was induced by free drinking of 3% DSS solution for 7 days, and SASP drug was administered orally at a dose of 400 mg / kg daily, divided into 2 doses, for 7 consecutive days; ALT711 low-dose group (denoted as ALT711 2.5 mg / kg group): UC was induced by free drinking of 3% DSS solution for 7 days, and ALT711 was administered orally at a dose of 5.0 mg / kg daily, divided into two oral administrations (2.5 mg / kg each time), for 7 consecutive days; The ALT711 high-dose group (denoted as ALT711 5.0 mg / kg group) was induced to have UC by freely drinking 3% DSS solution for 7 days. At the same time, ALT711 was administered orally at a dose of 10.0 mg / kg daily, divided into two doses (5.0 mg / kg each time), for 7 consecutive days.
[0022] The weight, stool and other abnormal conditions of mice in each group were recorded daily, and the disease activity index (DAI) score was obtained in a blinded manner. The mice were killed on the 8th day and cervical dislocation was performed for autopsy and sampling. Figure 1 , Figure 1 The effect of ALT711 on DSS-induced UC mice is shown, where: (A) The picture shows the effect of ALT711 on the colon length change of DSS-induced mice; (B) The picture shows the measurement data of the colon length change of mice; (C) The picture shows the weight change curve of mice; (D) The picture shows the DAI change curve. Compared with the control group, # P<0.05, ### P<0.001; *P<0.05 compared with the model group.
[0023] Depend on Figure 1 It can be seen that ALT711 can significantly inhibit the weight loss of mice, especially the ALT711 high-dose group (5.0 mg / kg); Figure 1 Figure D in the middle shows that ALT711 significantly improved the DAI score. Figure 1 As shown in Figures A and B, the colon length of mice in the DSS group was significantly shortened compared to the control group, while ALT711 significantly improved the colon length of mice treated with DSS. In summary, ALT711 can significantly improve the symptoms of UC in mice.
[0024] Example 2 This example used ALT711 to administer to DSS-induced UC mice, tracked colon changes in UC mice, and evaluated histological scores. The following steps were performed: Mice were treated as in "Experimental Example 1". After cervical dislocation, the colon tissues of all mice in the five groups were isolated, measured, and photographed as soon as possible. The colon contents were removed, fixed with 4% paraformaldehyde, embedded, sectioned, stained, and photographed under a microscope. Pathological changes such as edema, adhesions, ulcers, and necrosis were observed, and histological scores were evaluated. The results are shown in Figure 2 , Figure 2 The effects of ALT711 on DSS-induced colonic pathology in UC mice are shown, where: (A) The picture shows HE staining of the colon of mice in each group; (B) The picture shows the pathological statistical results. Compared with the control group, ### P<0.001; ***P<0.001 compared with the model group.
[0025] Depend on Figure 2 It can be seen that the colon damage of DSS-induced UC mice in the ALT711 (2.5 and 5.0 mg / kg) groups was milder. Therefore, it can be seen that the administration of ALT711 can significantly alleviate the pathological changes of colon damage in DSS-induced UC mice and significantly improve the histopathological score of colon inflammation.
[0026] Unless otherwise specified, the raw materials and equipment used in the present invention are commonly used in the art; the methods used in the present invention are conventional methods in the art unless otherwise specified.
[0027] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any way. Any simple modification, change and equivalent transformation made to the above embodiment based on the technical essence of the present invention still fall within the scope of protection of the technical solution of the present invention.
Claims
1. Use of ALT711 in the preparation of drugs for preventing and / or treating inflammatory bowel disease.
2. The use according to claim 1, characterized in that: The dosage forms of the drug include granules, ordinary tablets, dispersible tablets, effervescent tablets, orally disintegrating tablets, lozenges, chewable tablets, capsules, soft capsules, microcapsules, pills, powders, drop pills, sustained-release preparations, controlled-release preparations, oral liquid preparations and injections.
3. Use of ALT711 in the preparation of drugs for preventing and / or treating ulcerative colitis.
4. The use according to claim 3, characterized in that: The dosage forms of the drug include granules, ordinary tablets, dispersible tablets, effervescent tablets, orally disintegrating tablets, lozenges, chewable tablets, capsules, soft capsules, microcapsules, pills, powders, drop pills, sustained-release preparations, controlled-release preparations, oral liquid preparations and injections.
5. A composition for treating inflammatory bowel disease, characterized in that: The active ingredient of the composition is ALT711.
6. The composition according to claim 5, characterized in that: The inflammatory bowel disease is ulcerative colitis.
7. The composition according to claim 5, characterized in that: The composition includes one or more pharmaceutically acceptable excipients.
8. The composition according to claim 5, characterized in that: The composition is prepared into granules, ordinary tablets, dispersible tablets, effervescent tablets, orally disintegrating tablets, lozenges, chewable tablets, capsules, soft capsules, microcapsules, pills, powders, drop pills, sustained-release preparations, controlled-release preparations, oral liquid preparations and injections.
